Nosocomial MRSA pneumonia: Data from recent clinical trials

Reviews on Recent Clinical Trials

Volumn 6, Issue 3, 2011, Pages 235-240

  Karvouniaris, M ^a   Makris, D ^a   Karabekos, D ^a   Zakynthinos, E ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Linezolid; MRSA; Pneumonia; Vancomycin

Indexed keywords

CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; RIFAMPICIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; DRUG EFFICACY; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCAL PNEUMONIA;

ACETAMIDES; ANTI-INFECTIVE AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CROSS INFECTION; DNA, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; PNEUMONIA, VENTILATOR-ASSOCIATED; POLYMERASE CHAIN REACTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VANCOMYCIN;

EID: 80051713752     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/157488711796575568     Document Type: Article

References (42)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1-12.
2. Bartlett J. Methicillin-resistant Staphylococcus aureus infections. Top HIV Med 2008; 16: 151-5.
3. CDC Department of Health and human services. Communityassociated MRSA information for clinicians. Date last modified: February 3, 2005. Available from: http: //www.cdc.gov.
4. Matouskova I, Janout V. Current knowledge of methicillin-resistant Staphylococcus aureus and community-associated methicillinresistant Staphylococcus aureus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152(2): 191-202.
5. Fang C-T, Shau W-Y, Hsueh P-R, et al. Early empirical glycopeptides therapy for patients with methicillin-resistant Staphylococcus aureus bacteraemia: impact on the outcome. J Antimicrob Chemother 2006; 57: 511-519.
6. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-903.
7. Kashuk JL, Moore EE, Price CS, et al. Patterns of Early and Late Ventilator-Associated Pneumonia Due to Methicillin - Resistant Staphylococcus aureus in a Trauma Population. J Trauma 2010; 69: 519-522.
8. Athanassa Z, Siempos II, Falagas ME. Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review. Eur Respir J 2008; 31: 625-632.
9. ATS: Guidelines for the Management of Adults with Hospitalacquired, Ventilator-associated, and Healthcare-associated Pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416.
10. Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007; 45 (3): 315-321.
11. Popovich KJ, Weinstein RA, Hota B. Are Community-Associated Methicillin-Resistant Staphylococcus aureus (MRSA) Strains Replacing Traditional Nosocomial MRSA Strains? Clin Infect Dis 2008; 46: 787-94.
12. Neofytos D, Kuhn B, Shen S, et al. Emergence of Staphylococcal Cassette Chromosome mec Type IV Methicillin-Resistant Staphylococcus aureus as a Cause of Ventilator-Associated Pneumonia. Infect Control Hosp Epidemiol 2007; 28: 1206-1209.
13. Lynch III JP. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119: 373S-384S.
14. Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med 1998; 129: 433-440.
15. Kollef MH, Morrow LE, Niederman MS et al. Clinical characteristics and treatment patterns among patients with ventilatorassociated pneumonia. Chest 2006; 129: 1210-1218.
16. Shorr AF, Tabak YP, Gupta V, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator- associated pneumonia. Critical Care 2006, 10: R97.
17. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med 2008; 121: 310-315.
18. Garrouste-Orgeas M, Timsit JF, Kallel H, et al. Colonization with methicillin-resistant Staphylococcus aureus in ICU patients: morbidity, mortality, and glycopeptide use. Infect Control Hosp Epidemiol 2001; 22: 687-692.
19. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med 2000; 132: 621-630.
20. Canadian Critical Care Trials Group: A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355: 2619-2630.
21. Stürenburg E. Rapid detection of methicillin-resistant Staphylococcus aureus directly from clinical samples: methods, effectiveness and cost considerations. Ger Med Sci 2009; 6: 1-19.
22. Ost DE, Poch D, Fadel A, et al. Mini-bronchoalveolar lavage quantitative polymerase chain reaction for diagnosis of methicillinresistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38(7): 1536-41.
23. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-3862.
24. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin MIC to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated and healthcare-associated pneumonia. chest; Prepublished online June 17, 2010; DOI 10.1378/chest.09-2453.
25. Kollef KE, Reichley RM, Micek ST, et al. The modified APACHE II score outperforms curb65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant staphylococcus aureus pneumonia. Chest 2008; 133: 363-369.
26. Knaus WA, Draper EA, Wagner DP, et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-829.
27. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious disease society of america/american thoracic society consensus guidelines on the management of com munity-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72.
28. Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic- pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically Ill patients? Clin Infect Dis 2006; 42: 1764-71.
29. Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-412.
30. Wunderink RG, Cammarata SK, Oliphant TH, et al. Linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia: continuation of a randomized, double-blind, multicenter study. Clin Ther 2003; 25: 980-992.
31. Stevens DL, Herr D, Lampiris H, et al. Linezolid versus Vancomycin for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections. Clin Infect Dis 2002; 34: 1481-90.
32. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin resistant Staphylococcus aureus in japan. J Antimicrob Chemother 2007; 60: 1361-1369.
33. Cepeda JA, Whitehouse T, Cooper B, et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J Antimicrib Chemother 2004; 53: 345-355.
34. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiologic response to linezolid versus vancomycin in ventilator associated pneumonia (VAP) due to methicillin-resistant Staphylococcus aureus (MRSA). Chest 2008; 1200-1207.
35. Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: A systematic review and meta-analysis. Crit Care Med 2010; 38 (9): 1802-8.
36. Nosocomial Pneumonia With Suspected Or Proven Methicillin- Resistant Staphylococcus Aureus (MRSA) (ZEPHYR) NCT00084266. Available from: http://clinicaltrials.gov/ct2/show/NCT00084266?term=linezolid&rank=10. Date Last Updated: July 6, 2010.
37. Welte T, Pletz MW. Antimicrobial treatment of nosocomial meticillin- resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. Int J Antimicrob Agents 2010; 36: 391-400.
38. Jung YJ, Koh Y, Hong S-B, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010; 38(1): 175-180.
39. Silverman JA, Mortin LI, VanPraagh ADG, Li T, Alder J. Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact. J Infect Dis 2005; 191: 2149-52.
40. Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus (ATTAIN1) Study NCT00107952. Available from: http://clinicaltrials.gov/ct2/show/results/NCT00107952?term=telavancin+and+pneumonia&rank=1§=X6015#outcome1. Date Last Updated: January 19, 2010.
41. Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus (ATTAIN2) StudyNCT00124020. Available from: http://clinicaltrials.gov/ct2/show/NCT00124020?term=telavancin&rank=6. Date last modified May 14, 2010.
42. Ceftobiprole in Hospital Acquired Pneumonia NCT00210964. Available from: http://clinicaltrials.gov/ct2/show/NCT00210964?term=ceftobiprole&rank=4. Date Last Updated: September 2, 2010.